Evidence-based role of PET imaging in cardiac and systemic sarcoidosis: an umbrella review of the current literature.

Q J Nucl Med Mol ImagingJun 16, 2026 (epub)
Clinical ResearchCardiologyRadiology (Diagnostic)

Flaminia Vocaturo, Elena Romano Gargarella, Andrea Guarneri et al.

✦ AI-curated · Sources linked

In 30 seconds

This umbrella review systematically evaluated the role of [18F]FDG PET/CT in diagnosing and managing cardiac and systemic sarcoidosis. The analysis of multiple systematic reviews and meta-analyses indicated that PET imaging is effective for identifying active disease and guiding treatment decisions, particularly in cases with cardiac involvement.

Key findings

  • [18F]FDG PET/CT is valuable for diagnosing active cardiac and systemic sarcoidosis.
  • PET imaging aids in risk stratification and therapeutic monitoring in sarcoidosis patients.
  • The review supports PET/CT's use when conventional diagnostic methods are inconclusive.

Why it matters

Understanding the utility of [18F]FDG PET/CT in sarcoidosis can enhance diagnostic accuracy and treatment strategies, particularly in complex cases where traditional methods fall short. This can lead to improved patient outcomes through more tailored management.

Source

PubMed · PMID 42299129

Published in Q J Nucl Med Mol Imaging. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Cardiology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.